Skip to content

Trisodium citrate versus heparin for locking tunnelled haemodialysis catheters: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN27307877
Enrollment
Unknown
Registered
2005-09-30
Start date
2005-02-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure Urological and Genital Diseases Unspecified renal failure

Interventions

Trisodium citrate versus heparin for locking tunnelled haemodialysis catheters.

Sponsors

Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any patient who require a new tunnelled catheter for haemodialysis. Patients fall into three groups: 1. Patients who present to the kidney unit of the UHNS with kidney failure needing maintenance haemodialysis 2. Patients who have to switch from peritoneal to haemodialysis because of problems with their peritoneal dialysis 3. Existing haemodialysis patients who need tunnelled catheters because their arterivenous fistulas or tunnelled catheters have failed The decision to place a tunnelled dialysis catheter is made by one of the renal consultants entirely on the basis of clinical need. Patients will be invited to take part prior to insertion of the tunnelled dialysis catheter. Randomisation will be by sealed envelopes. The only differences in dialysis care that patients will have is the locking agent, otherwise patients will have the same treatment whether they are dialysing in our main renal unit in Stoke or our two satellite units at Stafford and Leighton. They will be followed up and all dialysis-related issues will be documented as per current practice.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Catheter blood flow of less than 250 ml/minute and/or venous pressure of more than 260 mmHg, persisting for one hour/session, in two consecutive sessions.

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026